Cellebrite (CLBT) Management Meeting: The Setup from Here
The SaaS apocalypse and whether AI replaces or improves their business.
We first highlighted Cellebrite (NYSE: CLBT) on January 2, 2025, and have held the position since. Of course, it has been hit hard by the “SaaS apocalypse.” Recently, we started receiving more questions around the story, so we decided it was a good time to jump on a call with the company.
If you’re new here and haven’t really looked into CLBT yet, no worries, we’ve included our initial report below, followed by an updated version so you are fully up to date and have a better understanding of what we are discussing in this post.
Before starting our recap of the call with the company, below is what we will cover. We kept it brief and focused on the most relevant points.
Table of Contents
Go-to-Market Strategy & Sales Model
AI Revenue Potential & Monetisation Strategy
Competitive Positioning & AI Disruption Risk
Market Perception & Operational Execution
Revenue Mix Evolution
Long-Term Risk Assessment in an AI Context
Our Updated Price Target